Displaying drugs 1251 - 1275 of 1989 in total
Phthalocyanine
Phthalocyanine is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
Investigational
Matched Iupac: … 2,11,20,29,37,38,39,40-octaazanonacyclo[28.6.1.1³,¹⁰.1¹²,¹⁹.1²¹,²⁸.0⁴,⁹.0¹³,¹⁸.0²²,²⁷.0³¹,³⁶]tetraconta …
Latozinemab
Investigational
Ibudilast
Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411...
Investigational
Matched Description: … Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 …
Somatropin pegol
Somatropin pegol is under investigation in clinical trial NCT00715689 (Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083).
Investigational
LL-37
LL-37 is a human cathelicidin that inhibits viral replication and while also playing a role in host defense against infection.
Investigational
MB-07803
MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
Investigational
MBT-0312
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
AZD-0424
AZD0424 has been used in trials studying the treatment of Advanced Solid Tumours.
Investigational
GDC-0927
GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer).
Investigational
VM4-037
VM4-037 is under investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037).
Investigational
SOBI-003
SOBI-003 is a chemically modified variant of a recombinant human sulfamidase. It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).
Investigational
YS-ON-001
YS-ON-001 is a combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium).
Investigational
TASO-001
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
ETBX-051
Investigational
EXOB-001
EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal cells.
Investigational
ABBV-011
ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.
Investigational
ABSK-091
Investigational
SLC-0111
Investigational
ICG-001
Investigational
iCo-007
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
PI-0824
Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide. People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort. Currently, most doctors who treat patients with PV will prescribe high-dose steroids...
Investigational
TRU-015
Investigational
PMI-001
PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis, lupus erythematosus and psoriasis.
Investigational
DNB-001
DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma. In preclinical animal models, DNB-001 has demonstrated potent IOP- lowering effects as well as neuroprotective effects on the optic nerve.
Investigational
Displaying drugs 1251 - 1275 of 1989 in total